biOasis Technologies Inc. is a ground-breaking biopharmaceutical company focused on the delivery of therapeutics across the blood-brain barrier (BBB) and into the brain tissue. The delivery of therapeutics across the BBB represents the single greatest challenge in the treatment of over a thousand common and rare diseases of the central nervous system. Fewer than 2% of medications are able to cross the BBB making this a large obstacle in patient treatment for brain diseases that affect 1 and 6 people worldwide.
biOasis is seeking to address these unmet medical needs with its proprietary Transcend Platform. Designed to transport therapeutics of varying types and sizes across the BBB, the Transcend Platform is based on Receptor Mediated Transcytosis, nature's own method of carrying compounds into the brain.
Preclinical animal studies have shown that biOasis’ patented technologies (MTf & MTfp) are able to deliver a variety of compounds into to the brain for treatments in the areas of oncology, metabolic diseases, neurodegenerative diseases and traumatic brain injury.
biOasis’ business strategy is to develop and commercialize its proprietary Transcend drug-delivery Platform through the advancement of high value internal therapeutic programs, while executing broad licensing models with pharmaceutical partners for the advancement of their therapeutics to clinical trials and commercialization.
biOasis’ brings together a highly experienced leadership team that is leveraging a strong patent strategy, robust development programs, combined with proven science to develop an effective drug delivery system, offering the market a new class of brain-penetrating drugs.
Located in Vancouver, Canada, biOasis is a publicly-traded company on the OTCQX under the symbol BIOAF and on the TSX Venture Exchange under BTI.
Visit us at www.biOasis.ca